Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

PubMed Links for Books (Select 1506680)

1.

A systematic examination of surface coatings on the optical and chemical properties of semiconductor quantum dots.

Smith AM, Duan H, Rhyner MN, Ruan G, Nie S.

Phys Chem Chem Phys. 2006 Sep 7;8(33):3895-903.

PMID:
19817050
2.

Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.

Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S.

Small. 2009 Feb;5(2):235-43. doi: 10.1002/smll.200800714.

3.

A pan-HER approach for cancer therapy: background, current status and future development.

Huang Z, Brdlik C, Jin P, Shepard HM.

Expert Opin Biol Ther. 2009 Jan;9(1):97-110. doi: 10.1517/14712590802630427 . Review.

PMID:
19063696
4.

The epidermal growth factor receptor ligands at a glance.

Schneider MR, Wolf E.

J Cell Physiol. 2009 Mar;218(3):460-6. doi: 10.1002/jcp.21635. Review.

PMID:
19006176
5.

Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ.

Curr Pharm Des. 2008;14(28):2983-98. Review.

6.

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.

Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, Biasco G.

Ann Oncol. 2009 Feb;20(2):213-26. doi: 10.1093/annonc/mdn625. Epub 2008 Oct 7. Review.

7.

Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN.

In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].

8.

Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.

Krause M, Baumann M.

Cancer Metastasis Rev. 2008 Sep;27(3):387-402. doi: 10.1007/s10555-008-9141-z. Review.

PMID:
18427731
9.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Engelman JA, Settleman J.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5. Review.

PMID:
18325754
10.

Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe.

Diagaradjane P, Orenstein-Cardona JM, Colón-Casasnovas NE, Deorukhkar A, Shentu S, Kuno N, Schwartz DL, Gelovani JG, Krishnan S.

Clin Cancer Res. 2008 Feb 1;14(3):731-41. doi: 10.1158/1078-0432.CCR-07-1958.

11.

Engineering antibodies for stability and efficient folding.

Honegger A.

Handb Exp Pharmacol. 2008;(181):47-68. Review.

PMID:
18071941
12.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD.

J Mol Biol. 2007 Aug 24;371(4):934-47. Epub 2007 May 10.

13.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P.

Cancer Res. 2006 Apr 15;66(8):3992-5.

14.

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.

Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD.

Cancer Biother Radiopharm. 2005 Dec;20(6):603-13.

PMID:
16398612
15.

In vivo cancer targeting and imaging with semiconductor quantum dots.

Gao X, Cui Y, Levenson RM, Chung LW, Nie S.

Nat Biotechnol. 2004 Aug;22(8):969-76. Epub 2004 Jul 18.

PMID:
15258594
16.

Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.

Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C.

Cancer Res. 2003 Nov 15;63(22):7870-5.

17.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M.

J Clin Oncol. 2002 Feb 1;20(3):719-26.

PMID:
11821453
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk